Positive Outlook for BioMarin Pharmaceutical Driven by Strong Financial Performance and Growth Opportunities

J.P. Morgan analyst Jessica Fye has maintained their bullish stance on BMRN stock, giving a Buy rating yesterday.

Jessica Fye’s rating is based on BioMarin Pharmaceutical’s strong financial performance in the second quarter, where the company reported higher-than-expected revenues driven by its enzyme business. The company also increased its 2025 non-GAAP EPS guidance, excluding Inozyme, due to slightly higher revenue projections and improved profitability, which suggests a positive outlook for future earnings.
Furthermore, BioMarin’s stock is considered undervalued, with a durable base business and potential for significant operating margin expansion in the coming years. The market’s current expectations for the medium to long-term prospects of Voxzogo are seen as overly pessimistic, providing an opportunity for growth. Additionally, the ongoing development of new products, such as the long-acting CNP product BMN 333, and strategic initiatives, including cost transformation, contribute to the positive assessment of the company’s future potential.

In another report released yesterday, Morgan Stanley also maintained a Buy rating on the stock with a $96.00 price target.